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Abstract  
Alterations in cortical thickness have been identified in major depressive disorder 
(MDD), but findings have been variable and inconsistent. To date, no reliable tools 
have been available for the meta-analysis of surface-based morphometric (SBM) 
studies to effectively characterize what has been learned in previous studies, and 
drug treatments may have differentially impacted findings. We conducted a 
comprehensive meta-analysis of magnetic resonance imaging (MRI) studies that 
explored cortical thickness in medication-free patients with MDD, using a newly 
developed meta-analytic mask compatible with Seed-based d Mapping (SDM) 
meta-analytic software. We performed the meta-regression to explore the effects of 
demographics and clinical characteristics on variation in cortical thickness in MDD. 
Fifteen studies describing 529 patients and 586 healthy controls (HCs) were included. 
Medication-free patients with MDD, relative to HCs, showed a complex pattern of 
increased cortical thickness in some areas (posterior cingulate cortex, ventromedial 
prefrontal cortex and anterior cingulate cortex) and decreased cortical thickness in 
others (gyrus rectus, orbital segment of the superior frontal gyrus, and middle 
temporal gyrus). Most findings in the whole sample analysis were confirmed in a 
meta-analysis of studies recruiting medication-naive patients. Using the new mask 
specifically developed for SBM studies, this SDM meta-analysis provides evidence 
for regional cortical thickness alterations in MDD, mainly involving increased 
cortical thickness in the default mode network and decreased cortical thickness in the 
orbitofrontal and temporal cortex.  
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Introduction 
Major depressive disorder (MDD) is a major cause of disability and contributor to 
the global burden of disease affecting more than 300 million people worldwide [1,2]. 
Despite its prevalence and disability, its neurobiological mechanisms remain 
incompletely understood. Magnetic resonance imaging (MRI) research has a 
significantly advanced understanding of brain changes associated with depression [3]. 
Many advances in clinical brain imaging research in recent years have been made 
possible by improvements in the measurement of distinct aspects of brain anatomy 
and function. In particular, advances in the measurement of cortical thickness, which 
reflects the size, arrangement, and density of neurons, nerve fibers and neuroglia, 
now can be performed with minimal partial volume effects that complicate brain 
volume estimates [4]. Advanced automated surface-based morphometric (SBM) 
methods, such as those available in FreeSurfer software, provide accurate models of 
the gray/white matter boundary and the pial surface of the cerebral cortex, measuring 
cortical thickness as the shortest distance between the 2 surfaces [5]. Cortical 
thickness abnormalities can be especially sensitive to regional disease-specific 
effects, including both neuroinflammation and other factors that can increase cortical 
thickness, and decreases in cortical thickness resulting from factors such as 
exuberant synaptic pruning and other causes of neuropil reduction [4,6]. 
Studies of cortical thickness in MDD have had variable results. Some have 
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reported increased cortical thickness in patients with MDD compared to healthy 
controls (HCs) in the orbitofrontal cortex (OFC) [7,8], rostral middle frontal gyrus 
[7], superior frontal gyrus [8], parietal cortex [9], temporal cortex [10,11], cingulate 
cortex [7,9], occipital cortex [12], and insula [11]. Other studies have reported 
decreased cortical thickness in MDD in the middle frontal gyrus as well as OFC 
[13,14], parietal cortex [15], temporal cortex [9,16], occipital cortex [13], insula [11], 
anterior cingulate cortex (ACC), and parahippocampus [17]; some studies have 
reported no cortical thickness differences in these regions [18,19]. These 
discrepancies may be explained by study differences in sample size, patient 
characteristics, clinical symptom severity, medication status, and image acquisition 
and processing protocols. By controlling for these, meta-analysis can help identify 
replicable and the most prominent cortical thickness alterations in MDD. 
Two meta-analyses have examined cortical thickness variation in MDD. The 
Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium 
used an individual participant data-based approach to analyze cortical thickness data 
from 2148 patients with MDD and 7957 HCs in 20 international groups, 
synthesizing data across participating sites rather than from published literature [20]. 
Suh and colleagues used Seed-based d Mapping (SDM) software 
(www.sdmproject.com) for systematic quantitative comparison and synthesis of 
published studies, including articles from outside the ENIGMA consortium [21].  
The inclusion of medicated patients may have biased the results for the 2 
studies. In addition, the ENIGMA consortium focused on cortical thickness in 
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regions of interest rather than every vertex of the cortex. In the absence of any 
specialized meta-analysis tool for SBM, Suh et al. used the gray matter mask 
designed for voxel-based structural studies [21]. Cortical gray matter volume is a 
function both of cortical thickness and surface area and in practice is more strongly 
correlated with the latter [4]. Cortical thickness is considered a heritable and 
relatively stable structural brain characteristic distinct from gray matter volume [22]. 
SDM includes masks for different brain tissues [23], but previously available gray 
matter mask in the SDM software includes all gray matter (i.e., cortical and 
subcortical). If a meta-analysis of cortical thickness performed using the gray matter 
mask in SDM, there would be an incongruence between the mask of the original 
studies (limited to cortical gray matter) and the mask of the meta-analysis, which 
could have an effect on cluster identification at cortical-subcortical boundaries and 
on significance testing given the different amount of brain tissue involved in 
analyses. Specifically, in the test of convergence using the gray matter mask, the 
addition of voxels with artificially null effect size (the subcortical gray matter) could 
lead to the imprecise estimations of the statistical significance and cluster number in 
the cortical gray matter. Given these limitations, there has been a need to optimize 
SDM software for meta-analyzing cortical thickness studies. A new mask is needed 
specifically for studies of cortical thickness, making the SDM output optimized for 
meta-analyzing cortical thickness results from FreeSurfer.  
Therefore, we set out to create a new meta-analytic mask in SDM to integrate 
the cortical thickness results of SBM studies in order to identify significantly 
©    2019 The Author(s). All rights reserved.
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replicable cortical thickness abnormalities in MDD across studies. We restricted our 
analysis to medication-free patients to reduce the potential impact of current/recent 
drug treatment on brain morphological changes. We hypothesized that: (i) compared 
with controls, medication-free patients with MDD would demonstrate cortical 
thickness alterations in OFC and ACC; and (ii) the identified altered cortical 
thickness would be associated with the severity of clinical features.   
©    2019 The Author(s). All rights reserved.
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Materials and Methods 
Search strategy and selection criteria 
The current meta-analysis was peformed according to the Preferred Reporting Items 
for Systematic reviews and Meta-Analyses guidelines (Table S1) [24]. The details of 
the search strategy and selection criteria are provided in Supplementary Methods. 
Two of us (Q.L. and Y.J.Z.) independently conducted the literature search. The 
results of these 2 searches were compared, and any inconsistencies were discussed 
and a consensus decision was reached about the appropriateness of the study for this 
meta-analysis. 
 
SDM meta-analysis 
Meta-analysis was conducted in SDM software (version 5.15), which has been used 
to meta-analyse MRI data acquired from patients with psychiatric disorders 
including obsessive-compulsive disorder [25], schizophrenia [26], and autism 
spectrum disorder [27]. When conducting a meta-analysis, it is necessary to select an 
appropriate mask (e.g. gray matter, white matter, TBSS) to restrict the signed 
differential map created for each included study. As the existing gray matter mask 
was not optimized for SBM studies, our first step was to adapt SDM by creating a 
new one (Figure 1). The steps in this process were: 1) resampling of FreeSurfer left 
and right hemisphere surface masks into volumes using the FreeSurfer command 
“mri_surf2vol”; 2) conversion of the volumes to NIfTI format with the FreeSurfer 
©    2019 The Author(s). All rights reserved.
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command “mri_convert”; 3) combining the 2 volumes (left and right hemisphere) 
into a single volume with the FSL command “fslmaths -add”; 4) performing a 12 
degree-of-freedom affine transformation of the volume from FreeSurfer space to 
FSL-MNI space using the FSL commands “flirt -applyxfm” and “fslmaths -thr 0.01 
-bin”; and 5) application of a narrow smoothing and binarization to make the mask 
slightly thicker and smoother (to avoid that it includes isolated voxels) with the FSL 
command “fslmaths -s 0.15 -bin”. In the pre-processing of the present meta-analysis, 
we found that nearly all (12 out of 13) of the maximum and minimum peak 
coordinates of the effect-size signed map of each included study were encompassed 
in the created cortical mask. 
Details of quality assessment (Table S2), data recording, SDM method of 
meta-analysis, jackknife, heterogeneity, publication bias analysis, and 
meta-regression are presented in supplementary methods. 
  
©    2019 The Author(s). All rights reserved.
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Results 
Included studies and sample characteristics 
Figure 2 shows the flowchart of the literature search and eligibility assessment. The 
final sample of 15 studies reported 529 medication-free patients with MDD (mean 
age 37.9 years) and 586 HCs (mean age 35.8 years); the meta-analysis incorporated 
47 peak coordinates extracted from 11 of those studies [7,9,11-17,28,29]. Four 
studies were included in analyses that found no cortical thickness differences 
between patients and HCs [10,18,19,30]. No study used overlapping patient samples. 
One study reported the coordinates of the peak on an inflated brain [29], so we 
converted the reported vertex numbers into the corresponding MNI coordinates that 
SDM requires, allowing consistent localization of alterations in cortical thickness for 
meta-analysis. 
Table 1 shows the demographic and clinical characteristics from studies included 
in the meta-analysis. All participants provided written informed consent. Among the 
15 studies, 7 recruited 224 drug-naive patients [7,9,13,15,19,28,29], while 4 studies 
included all off-medication but previously treated patients [10,11,18,30], and 4 studies 
recruited combined samples of off-medication and drug-naive patients [12,14,16,17]. 
The mean duration of illness was smaller in the drug-naive patients than the currently 
untreated patients (1.0 years vs 9.2 years). The minimum time off-medication in the 
studies of patients off medication included in our current study was at least 1 week (1 
week, 1 study; 2 weeks, 1 study; 1 month, 1 study; 6 weeks, 1 study; 2 month, 1 study; 
©    2019 The Author(s). All rights reserved.
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and 6 month, 1 study) according to the 6 studies that reported the duration of the 
medication-free period before scans were performed [10,11,14,16,18,30]. We 
considered all of these patients together as “medication-free” in our primary analysis.  
Three studies reported that some patients had comorbid psychiatric disorders 
(primarily anxiety disorder) [14,15,30], while the other 12 reported recruiting only 
patients without comorbidities. In 14 studies the threshold was corrected for multiple 
comparisons, but 1 study used an uncorrected threshold [15]. We also conducted 
separate subgroup meta-analyses in the 12 studies with 425 non-comorbid patients 
and 14 studies with threshold correction for comparison purposes. 
The mean age of patients and the percentage of female patients were available in 
all 15 studies. In our meta-analysis, there was no significant difference between 
patients with MDD (male, 197; female, 332) and HCs (male, 252; female, 334) in 
gender ratios (P=0.05). Thirteen out of the 15 included studies reported the P values 
for the comparison of age between groups without significant differences 
[7,9-16,19,28-30]. For the 2 studies without the P values for age comparisons, 
Wagner et al. stated there were no differences in age between patients with MDD and 
HCs in their study without reporting the specific P value [17]. Taylor et al. recruited 3 
groups in their study with depressed patients without and with thoughts of death and 
healthy controls, and they reported a significant difference in age among the 3 groups 
(P<0.0001) [18]. Although Taylor et al. did not demonstrate the result of age 
compared between all the patients (both without and with thoughts of death) and 
controls, age was controlled as a covariate for all the group comparisons of cortical 
©    2019 The Author(s). All rights reserved.
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thickness [18]. 
The age at onset and illness duration of patients were available for 7 studies 
[9-12,16,17,30] and 11 studies [7,9,12,13,15-19,29,30], respectively. The mean 
number of episodes of illness in currently medication-free patients with MDD in 14 
studies was 1.86, but unreported and unavailable in 1 study [30]. To evaluate illness 
severity at the time of testing of patients with MDD, 9 studies [7,10-13,19,28-30], 1 
study [17], and 3 studies [9,15,16] used the 17-, 21-, and 24-item versions of the 
Hamilton Depression Rating Scale (HDRS), respectively. One study used the Beck 
Depression Inventory [14], and 1 study used
 
the Montgomery-Asberg Depression 
Rating Scale [18]. Based on the recommendation that meta-regression requires at least 
9 studies [25], we explored by meta-regression the association with cortical thickness 
of age (15 studies), percentage of female patients (15 studies), illness duration (11 
studies), number of episodes (14 studies), severity of illness (9 studies with 17-item 
HDRS). 
 
SDM meta-analysis 
For all 15 studies included in the pooled meta-analysis, compared with HCs, 
medication-free patients with MDD showed increased cortical thickness in the left 
posterior cingulate cortex (PCC) (Z=1.113, P=0.00135) and right ventromedial 
prefrontal cortex (vmPFC) extending to left ACC (Z=1.178, P=0.00087), and 
decreased cortical thickness (cortical thinning) in the left gyrus rectus (Z=−1.412, 
P=0.00027), left orbital segment of superior frontal gyrus (oSFG) (Z=−1.162, 
©    2019 The Author(s). All rights reserved.
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P=0.00132), and right middle temporal gyrus (MTG) (Z=−1.144, P=0.00146) (Table 
2 and Figure 2). The subgroup meta-analysis results in studies with non-comorbid 
patients and with threshold correction (Table S3 and S4) were highly consistent with 
the pooled findings (Table 2). Most of the results between the medication-naive 
subgroup meta-analysis and the pooled meta-analysis were consistent 
(Supplementary Results, Table S8, and Figure S2). 
 
Jackknife, heterogeneity and publication bias analysis  
In whole-brain jackknife sensitivity analysis, decreased cortical thickness in left 
gyrus rectus, left oSFG and right MTG, and increased cortical thickness in right 
vmPFC extending to left ACC, were preserved in 14 combinations of 15 datasets, 
while increased cortical thickness in the left PCC remained significant in 13/15 
datasets (Table S5); the results of the pooled meta-analysis thus showed high 
replicability and reliability in those regions. So did the jackknife sensitivity analysis 
of the subgroup meta-analyses in studies with non-comorbid patients and threshold 
correction (Table S6 and S7). For the jackknife sensitivity analysis of the subgroup 
meta-analysis in studies with medication-naive patients with MDD, the cortical 
thickness in the orbital part of right middle frontal gyrus and left oSFG were 
preserved in 6 combinations of 7 studies while the finding in right vmPFC was 
preserved in 4 combinations (Table S9).  
In the pooled meta-analysis, none of the regions with altered cortical thickness 
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(Table 2 and Figure 3) showed statistical heterogeneity between studies (all 
P>0.005). In the analysis of publication bias, the Egger test of funnel plot asymmetry 
was not significant in the left PCC (Z=1.21, t=1.00, df=13, P=0.335), right vmPFC 
extending to left ACC (Z=−0.27, t=−0.21, df=13, P=0.834), left gyrus rectus 
(Z=−1.41, t=−0.83, df=13, P=0.419), left oSFG (Z=0.95, t=0.90, df=13, P=0.440), or 
right MTG (Z=0.02, t=0.01, df=13, P=0.989) (Figure S1). 
 
Meta-regression analysis 
The percentage of female patients with MDD was negatively associated with 
decreased cortical thickness in the left gyrus rectus (r=−0.433, P=0.00020) (Figure 
4). This result was driven by 4 studies [12,15,17,29]. Neither mean age of patients, 
age at onset, illness duration, number of episodes, or illness severity were 
significantly associated with cortical thickness alterations.  
  
©    2019 The Author(s). All rights reserved.
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Discussion  
To our knowledge, this is the first meta-analysis of vertex-based FreeSurfer studies 
to identify a significant and complex pattern of cortical thickness alteration in 
untreated patients with MDD. It also incorporates a significant methodological 
innovation. A new mask was specifically designed for the meta-analysis of cortical 
thickness and will be made freely available in SDM software for use in future 
meta-analyses. 

 Using the new mask, we identified replicable increased cortical 
thickness in the default mode network (DMN) (PCC, vmPFC, and ACC), and 
decreased cortical thickness in OFC (gyrus rectus and oSFG) and temporal cortex in 
medication-free patients with MDD. In addition, we found a negative correlation 
between the percentage of female patients and cortical thickness alterations in gyrus 
rectus. 
Previous meta-analyses reported gray matter loss (decreased gray matter 
volume/density) in the frontal cortex, temporal lobe, OFC and cingulate cortex in 
patients with MDD [31,32], regions with observed alterations in our study. 
Consistent with the previous meta-analysis conducted by the ENIGMA consortium 
[20], we identified cortical thickness alterations in OFC, ACC, PCC, and MTG. Of 
note, we found increased cortical thickness in ACC and PCC, while ENIGMA 
consortium reported changes in the opposite direction. The difference in findings 
might be related to the ENIGMA patients being typically treated and later in illness 
course than participants of studies in our meta-analysis. Compared to the study by 
                                                             
 Note to reviewers: we will include the mask in SDM software once this paper is accepted for publication. 
©    2019 The Author(s). All rights reserved.
 16 
 
Suh et al. [21], we did not observe cortical thickness abnormalities in pars 
opercularis, calcarine fissure/lingual gyrus or supramarginal gyrus in patients with 
MDD. The reasons for these differences might be attributable to the heterogeneities 
of mask selection and medication status of patients with MDD. 
 
Increased cortical thickness in the DMN in MDD 
Understanding of the pathophysiology of MDD has progressed steadily, including 
improved understanding of the role of genes, inflammation, and changes in brain 
anatomy and function [3]. Previous neuroimaging studies in MDD found structural 
and functional brain abnormalities mainly in the medial prefrontal-limbic circuit 
(areas modulated by serotonin neurotransmission and related to emotion regulation) 
and the orbitofrontal-striatal network (modulated by dopamine and underpinning 
reward processing) [33,34]. Previous studies focused on the connectivity stability in 
MDD have also demonstrated the great importance of DMN [35,36]. Patients with 
MDD show a stronger functional correlation between the anterior parts of DMN and 
the amygdala during self-referential processing and elevated functional connectivity 
(FC) between the dorsal and rostral parts of ACC during cognitive and affective 
challenges [37]. A meta-analysis of resting-state FC in MDD has confirmed 
functional hyper-connectivity within DMN [38]. Patients with MDD also show 
greater DMN activity in the resting-state and less deactivation of that network during 
cognitive processing [39]. The brain regions with increased cortical thickness 
©    2019 The Author(s). All rights reserved.
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identified in the present meta-analysis (PCC, vmPFC, and ACC) are important hubs 
in the DMN [40], which is involved in affective processing and self-referential 
processing [41]. These structural alterations may be related to the failures to 
deactivate DMN regions during cognitive activity, and perhaps represent a 
consequence of neuronal hyperactivity over time in the regions.  
Yan et al. found decreased DMN FC in recurrent MDD (mean illness duration 
7.7 years), which was associated with medication usage [42], while Kim and 
colleagues observed increased DMN FC in the first episode, drug-naive patients with 
MDD [43]. These divergent findings suggest a potential trajectory of FC in DMN 
over the course of illness in MDD. In our study, the median illness duration was only 
1.2 years in 11 of our studies, so that our findings of increased thickness in DMN 
regions may align with increased functional reported in the Kim study. 
The vmPFC and ACC are involved with mood regulation and higher-order 
cognitive processing [44,45], and increased cortical thickness in these areas might be 
related to symptoms including anhedonia, negative thinking, and changes in 
emotional experience associated with MDD [45]. Functional imaging evidence has 
reported ACC hyperactivation in MDD, which was a predictive biomarker for 
treatment response [46]. The left PCC, another region with increased cortical 
thickness, plays an essential role in arousal, and internal vs. external focus of thought 
and attentional focus [47]. The vmPFC can regulate PCC activity that is enhanced 
during explicit self-appraisal; in MDD, and alteration of this regulation may 
contribute to disturbances of self-appraisal that are a critical feature of the illness 
©    2019 The Author(s). All rights reserved.
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[45]. van Eijndhoven et al. found that increased cortical thickness in caudal ACC and 
PCC were trait-related in first-episode patients with MDD [12], suggesting that ACC 
and PCC alterations may play a vital role in the early stage of MDD. 
The mechanism of increased cortical thickness in MDD is unclear, although one 
could speculate that it may result from the dual activation of the 
immune-inflammatory response system and the compensatory immune-regulatory 
reflex system [48]. Possible causes of increased cortical thickness observed in some 
brain regions include pre-apoptotic osmotic changes (partly induced by increased 
cytokines), cellular hypertrophy, and cytokine-activated astrocyte proliferation 
[49,50]. For instance, interleukin-1β, which has been reported to be increased in 
patients with MDD [51], could induce astrocyte nuclear hypertrophy [52]. Astrocytes 
play a critical role in the blood-brain barrier; their energy metabolism helps prevent 
excitotoxicity and they release neurotrophic factors which assist neuronal survival 
and formation of new synapses [49]. Such compensatory mechanisms may be 
particularly relevant early in MDD, as cortical thickness and activity seem to be 
increased in some regions early in the illness course but decrease as the illness 
progresses. While we did not observe any significant correlation between cortical 
thickness and illness duration in our study of untreated patients, this may be due to 
the typically short illness duration of samples recruited in studies included in our 
meta-analysis. The exact pathological mechanisms underlying increased cortical 
thickness in medication-free patients with MDD requires further investigation. 
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Orbitofrontal and temporal cortical thinning in MDD 
Decreased cortical thickness was seen in OFC regions including the left gyrus rectus 
and the oSFG. The OFC contributes to reward processing, exteroceptive and 
interoceptive information coding, impulse control, mood regulation, and decision 
making [53], and so OFC abnormalities may contribute to commonly observed 
emotional and cognitive impairments in depression. Consistent with our finding of 
decreased cortical thickness in these regions, both structural (decreased gray matter 
volumes [54]) and functional (decreased regional homogeneity [55], cerebral blood 
flow [56], and amplitude of low-frequency fluctuations [56]) studies in MDD have 
reported abnormalities in OFC. In addition, van Eijndhoven et al. reported that 
decreased thickness of OFC was related to trait anxiety and altered mood regulation 
in MDD [12]. Peterson et al. found decreased cortical thickness in left OFC in 
individuals at increased familial risk for MDD [57], suggesting that cortical thinning 
of left OFC may precede illness onset or reflect alterations related to risk for MDD. 
A higher percentage of female patients with MDD in studies included in current 
meta-analysis was associated with the reduction of cortical thickness in the left gyrus 
rectus. Sex difference in MDD is important, as females show a prevalence of MDD 
in nearly twice that of males [58], have a higher rate of psychiatric comorbidities and 
make more frequent suicide attempts [59]. A previous meta-analysis of gray-matter 
volume studies of MDD found smaller prefrontal cortex in female than male patients 
[54], consistent with our findings.  
Interestingly, OFC expresses high concentrations of glucocorticoid receptors 
©    2019 The Author(s). All rights reserved.
 20 
 
and thus is vulnerable to injury induced by increased glucocorticoid levels [60], 
including increased sensitivity to excitotoxic injury and neuron death [61]. 
Consistent with this, a negative correlation has been reported between cortical 
thickness in OFC and serum cortisol levels [28]. There is also evidence that 
increased interleukin-6 is inversely correlated with the cortical thickness of OFC in 
MDD [13], and that it controls the expression of the serotonin transporter and 
consequently serotonin reuptake, with potential relevance for behavioral features of 
MDD [62]. In addition, high-sensitivity C-reactive protein has been related to 
reduced gray matter volume in the prefrontal cortex, indicating the potential role of 
inflammatory activation in the anatomic alterations associated with MDD [63]. 
Further, there is postmortem evidence for a reduced density of pyramidal neurons in 
OFC that could contribute to the decreased cortical thickness of OFC observed in 
our meta-analysis of MDD [64].  
The area of posterior MTG identified to show reduced cortical thickness is well 
known as a region controlling the perception of dynamic moving objects [65,66]. 
This region is important for regulating sensorimotor responses to visual motion, 
which are impaired in MDD [67]. Alterations in this region may contribute to the 
perceptual analysis of social and other dynamic visual events. In addition, the MTG 
plays an important role in facial emotion perception, which is related to nonverbal 
social communication, and thus MTG abnormalities might be expected to affect 
interpersonal engagement and social functioning [68,69]. Previous neuroimaging 
studies of MDD have reported decreased gray matter volume [70], reduced 
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functional activity [71], and disrupted functional network connectivity in MTG [72]. 
Our results, taken together with these, are consistent with a role for MTG alterations 
in MDD. 
 
Potential etiological implications 
One of the most striking features of our meta-analysis was the demonstration of a 
complex pattern of regional dystrophic and hypertrophic alterations in MDD evident 
across studies of medication-free patients with MDD. While our meta-analysis 
summarizes this pattern of effects, it also raises questions and suggests paths for 
productive future research. Previous evidence shows that the alterations in 
immune-inflammatory systems can be associated with both increased and decreased 
cortical thickness. Poletti et al. observed that increased inﬂammatory markers such 
as tumor necrosis factor-α, interleukin-8, and chemokine (CCmotif) ligand were 
correlated with the increased cortical thickness of ACC in patients with bipolar 
depression [73]. Piras and colleagues observed that increased transforming growth 
factor β (TGF-β) was associated with increased cortical thickness in cingulate and 
frontal areas in healthy individuals [74]. The role of TGF-β in down-regulating 
inflammatory processes and in promoting repair mechanisms might be related to the 
observed increased cortical thickness [75]. One study of mice showed that maternal 
immune activation during pregnancy was associated with increased cortical 
thickness in their offspring [76]. Kakeda et al. found that reduced cortical thickness 
in orbital frontal cortex in patients with MDD was negatively correlated with 
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increased interleukin-6 levels [13]. 
Based on the evidence that the OFC expresses high concentrations of 
glucocorticoid receptors mentioned above [77], while Alt et.al. reported the MDD 
patients exhibited significantly decreased glucocorticoid receptor-α density in the 
cingulate cortex [78], such factors might account for variable patterns of cortical 
thickness changes across the brain rather than a consistent effect across cortex. We 
speculated that cortical thickening in certain brains regions and cortical thinning in 
other brain regions might be due to heterogeneities of response sensitivity or 
differing time course of evolving neuronal alterations related to illness 
pathophysiology in MDD. Why immune-inflammatory related factors would alter 
regional brain activity and anatomy selectively in this way remains to be determined. 
Further neurobiological and neurobehavioral studies of these 2 patterns of alterations 
are needed to clarify their clinical significance and underlying mechanisms. 
 
Limitations 
First, like most coordinate-based meta-analysis studies, we summarized data (i.e. 
reported coordinates) rather than raw data from individual cases, which limits 
precision in the characterization of the precise and full spatial location of effects. 
Furthermore, we could not obtain coordinates for all prior studies, despite our efforts 
to contact the authors of otherwise suitable studies [79-83]. Second, our 
meta-regression finding that the percentage of female patients was negatively 
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correlated with cortical thickness in left gyrus rectus was driven by 4 studies, and 
thus it requires further confirmation. Third, since the present meta-analysis focused 
on cross-sectional studies, longitudinal studies are needed to determine the degree to 
which cortical thickness changes in MDD diminish or progress after clinical 
recovery and antidepressant therapy. Fourth, because the number and sample sizes of 
prior studies of drug-naive patients were limited, we included studies of previously 
treated patients who were untreated before MRI scanning. Although previous study 
reported no significant differences in resting-state brain activity between drug-naive 
and currently off-medication patients with MDD [84], the potential influences of 
prior medication on cortical thickness could not be completely excluded. Clearly, the 
best way to minimize the effects of medication on brain measures is to focus on 
drug-naive patients with MDD because the drug-naive and untreated conditions may 
not be the same in relation to associated brain abnormalities. However, studying 
currently untreated patients is of interest to determine whether different alterations 
are present from those associated with the never treated illness that may indicate 
“scars” of prior episodes or enduring effects of prior treatment. Meta-analysis 
comparing medication-naive and currently off-medication patients with MDD are 
needed when the number of published studies of both types permits. Finally, there 
were some potential limitations of this specific meta-analytic mask. An obvious 
limitation (and benefit) of the mask created and used in the present meta-analysis is 
that it only includes cortical gray matter. Therefore, we recommend the standard 
gray matter mask (instead of the new mask) for meta-analyses that include 
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subcortical gray matter (e.g. VBM). Another limitation related to the mask is that we 
created the mask based on the FreeSurfer mask, and this may have slight differences 
with other surface-based analysis software and procedures. We suspect that such 
differences will be minor and thus have a small or negligible impact on results. 
 
Conclusion 
In conclusion, by applying a new mask in SDM and focusing on the medication-free 
patient with MDD for the present meta-analysis, we identified significant regional 
cortical thickness alterations in MDD, including increased cortical thickness in 
DMN (PCC, vmPFG, and ACC) and decreased cortical thickness in OFC and MTG. 
Meta-regression suggests that female medication-free patients with MDD may have 
a lower cortical thickness in left gyrus rectus. These findings in untreated patients 
where pharmacological treatment effects could have a limited impact on brain 
measurements identified important new information about intrinsic structural brain 
alterations in patients with MDD.   
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Figure Legends 
Figure 1. The demonstration of the newly created mask and the mask of gray 
matter previously available in SDM software. 
The demonstration of the newly created mask special for meta-analyzing the 
surface-based morphometric studies in the present study (A) and the existing mask 
of gray matter for meta-analyzing voxel-based structural studies in SDM software 
(B) 
 
Figure 2. Flowchart of literature search and selection criteria.  
Search terms were ((depression OR depressive disorder OR unipolar depression) 
AND (cortical thickness OR thickness)).  
 
Figure 3. Cortical thickness alterations in medication-free patients with major 
depressive disorder compared to healthy controls. 
Regions of increased (warm color) and decreased (cool color) cortical thickness in 
medication-free patients with MDD than HCs in the pooled meta-analysis. 
Abbreviations: ACC, anterior cingulate cortex; GR, gyrus rectus; L, left; oSFG, 
orbital segment of the superior frontal gyrus; PCC, posterior cingulate cortex; 
vmPFC, ventromedial prefrontal cortex; MTG; middle temporal gyrus; R, right. 
 
Figure 4. The results of meta-regression analysis. 
The percentage of female patients with the major depressive disorder was negatively 
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correlated with cortical thickness in the left gyrus rectus in the meta-regression. The 
effect sizes to create this plot were extracted from the peak of the maximum slope 
difference and each study is represented as a dot. The regression line 
(meta-regression signed differential mapping slope) is shown.  
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Table 1. Demographic and clinical characteristics of participants in the 15 included studies. 
Study 
Number (female)  Age at study, y 
Age of 
onset, y  
Illness 
duration, 
y 
Mean 
number of 
episodes 
Statistic of cortical 
thickness 
(correction) 
Score of 
Severity 
(scale type) 
Medication status 
Scanner field 
strength 
(Tesla) 
Voxel 
Size (mm
3
) MDD HCs 
P value 
for sex 
 MDD HCs 
P value 
for age 
Han et al., 2014[19] 20 (15) 22 (15) 0.63  42.7 43.7 0.81 NA 0.4 1.8 P<0.05 (MCS) 19 (HDRS-17) All naive 3.0 1.0×1.0 ×1.0 
Kakeda et al., 2018[13] 40 (20) 47 (13) 0.05  46.6 40.7 0.06 NA 0.5 1.0 P<0.05 (MCS) 22 (HDRS-17) All naive 3.0 0.9×0.9×1.2 
Lan et al., 2014[30] 56 (32) 54 (26) 0.65  36.9 31.8 0.06 23.4 13.6 NA P<0.05 (MCS) 24 (HDRS-17) All Untreated>2 weeks 3.0 1.0×1.0×1.0 
Liu et al., 2015[28] 30 (13) 41 (13) 0.32  44.9 41.2 0.22 NA NA 1.0 P<0.05 (MCS) 21 (HDRS-17) All naive 3.0 0.9×0.9×1.2 
Na et al., 2014[29] 45 (34) 72 (51) 0.31  41.6 40.7 0.35 NA 2.5 1.8 P<0.05 (MCS) 20 (HDRS-17) All naive 3.0 1.0×1.0×1.0 
Niu et al., 2017[16] 36 (19) 30 (13) 0.68  29.1 27.8 0.78 24.9 3.5 1.8 P<0.05 (MCS) 27 (HDRS-24) Untreated>6 months (n=17) 
Naive (n=19) 
3.0 NA 
Peng et al. ,2015[9] 16 (9) 16 (9) 1.00  34.4 33.9 0.77 33.3 0.2 1.0 P<0.05 (FDR) 31 (HDRS-24) All naive 3.0 0.9375× 0.9375×1.0000 
Qiu et al., 2014[7] 46 (33) 46 (33) 1.00  34.9 35.4 0.58 NA 0.4 1.0 P<0.05 (FDR) 23 (HDRS-17) All naive 3.0 NA 
Späti et al., 2015[14] 21 (10) 35 (20) 0.49  36.6 32.7 >0.2 NA NA 6.0 P<0.05 (MCS) 26 (BDI) Untreated>6 weeks (n=5) 
Naïve(n=16) 
3.0 0.94×0.94×1.00 
Taylor et al., 2015[18] 74 (52) 91 (56) 0.24  36.4 29.9 NA
b
 NA 5.9 3.1 P<0.05 (MCS)
d
 24 (MADRS)  All Untreated>1 month 3.0 0.9×0.9×1.2 
van et al., 2013[12] 40 (27) 31 (19) 0.95  35.0 34.7 0.90 33.6 1.2 1.0 P<0.05 (FDR) 13 (HDRS-17) Untreated (n=20)
a
/naive (n= 20) 1.5 1.0×1.0×1.0 
van et al., 2016[10] 23 (15) 22 (14) 0.91  50.7 50.8 0.98 40.8 NA 2.8 P<0.05 (MCS) 22 (HDRS-17) All Untreated>1 week 1.5 1.0×1.0×1.0 
Wagner et al., 2012[17] 30 (25) 30 (25) 1.00  37.6 35.1 NA
c
 31.6 6.0 1.3 P<0.05 (MCS) 25 (HDRS-21) Untreated (n=23)
a
/naive (n=7) 1.5 1.0×1.0×1.0 
Yang et al., 2015[15] 27 (13) 27 (13) 1.00  28.6 28.7 0.07 27.8 0.8 1.0 P<0.001 (Uncorr) 28 (HDRS-24) All naive 3.0 1.0×1.0×1.0 
Zorlu et al., 2017[11] 25 (15) 22 (14) 0.71  36.7 38.5 0.45 30.6 NA 1.7 P<0.05 (MCS) 26 (HDRS-17)  All Untreated>2 months 1.5 1.0×1.0×1.0 
a
 These studies did not report the period of the untreated state. 
b 
Although this study did not demonstrate the result of age compared between all the patients (both 
without and with thoughts of death) and controls, age was controlled as a covariate for all the group 
comparisons of cortical thickness. 
c This study didn’t report the P values of mean age, but they stated no differences in age between 
patients with MDD and HCs. 
d
 The author confirmed that there were no significant differences in cortical thickness between the 
control group and the entire MDD group by email. 
Abbreviations: BDI, Beck Depression Inventory; FDR, false discovery rate; HCs, healthy controls; 
HDRS-17/21/24,17/21/24-item Hamilton Depression Rating Scale; MADRS, Montgomery–Asberg 
Depression Rating Scale; MCS, Monte Carlo simulations; MDD, major depression disorder; NA, not 
available; Uncorr, uncorrected; y, year. 
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Table 2. Differences in cortical thickness between medication-free patients with 
major depressive disorder and healthy controls. 
 
Region 
MNI coordinate   SDM 
P, 
uncorrected 
Voxels Cluster breakdown (voxels) 
x y 
z Z 
score 
Patients with major depressive disorder > healthy controls 
Left posterior 
cingulate cortex 
0 -24 34 1.113 0.00135 471 Left posterior cingulate / paracingulate gyri, BA 
23 (206) 
Right posterior cingulate / paracingulate gyri, BA 
23 (141) 
Median network, cingulum (124) 
Right 
ventromedial 
prefrontal cortex 
8 50 2 1.178 0.00087 208 Right superior frontal gyrus, medial, BA 10 (91) 
Left anterior cingulate / paracingulate gyri, BA 
24, 32 (85) 
Left median network, cingulum (23) 
Right anterior cingulate / paracingulate gyri, BA 
10, 24, 32 (9) 
Patients with major depressive disorder < healthy controls 
Left gyrus 
rectus 
-4 32 -26 -1.412 0.00027 629 Left gyrus rectus, BA 11 (491) 
Left superior frontal gyrus, orbital part, BA 11 
(78) 
Left superior frontal gyrus, medial orbital, BA 11 
(47) 
Right gyrus rectus, BA 11 (13) 
Right middle 
temporal gyrus 
46 -72 10 -1.144 0.00146 89 Right middle temporal gyrus, BA 19, 37, 39 (78) 
Right middle occipital gyrus, BA 19, 37 (11) 
Left superior 
frontal gyrus, 
orbital part 
-16 58 -8 -1.162 0.00132 63 Left superior frontal gyrus, orbital part, BA 11 
(60) 
Left middle frontal gyrus, orbital part, BA 11 (3) 
Abbreviations: BA, Brodmann area; MNI, Montreal Neurological Institute; SDM, Seed-based d 
Mapping. 
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